How safe is enlicitide? Evidence from the CORALreef trials

Questions about enlicitide side effects and safety profile became clinically immediate in mid-July 2026, when the FDA approved Lipfendra as the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia who need additional LDL-C lowering. [1][2] The approval matters because oral dosing removes a familiar barrier around injectable PCSK9 therapy. It does not, by itself, answer the practical question that follows every new lipid prescription: once this tablet is added to statins, ezetimibe, diabetes drugs, antihypertensives, and supplements, what adverse effects should clinicians expect, and how often did they matter enough to stop treatment?

The most useful starting point is not the novelty of an oral PCSK9 inhibitor, but the pivotal 52-week placebo-controlled safety table. In CORALreef Lipids, 2,904 adults with hypercholesterolemia were assigned to enlicitide or placebo and followed for 52 weeks. [3] Across that trial, overall adverse events, serious adverse events, discontinuations due to adverse events, and deaths were similar between groups.

That table supports a restrained version of the phrase “placebo-like.” It means that, in a controlled 52-week trial of adults with hypercholesterolemia, enlicitide did not produce an excess in the safety outcomes that usually shape prescribing confidence: serious events, treatment-stopping events, or mortality. [3] It does not mean every symptom reported after prescribing will be unrelated, and it does not extend automatically to patients excluded from the trial.

What the 52-week placebo comparison actually shows

The overall adverse-event rate was close: 64.3% with enlicitide and 62.1% with placebo, a 2.2 percentage-point difference with a 95% confidence interval from -1.5 to 5.9. [3] For a daily oral medication, that is a useful broad tolerability signal, but it is also the least specific safety measure. In lipid clinics, mild intercurrent symptoms are common in older, cardiometabolic populations; the harder question is whether those symptoms translate into serious harm or treatment abandonment.

On that point, CORALreef Lipids is more reassuring. Serious adverse events occurred in 9.9% of enlicitide-treated participants and 12.0% of placebo-treated participants. [3] The trial was not a proof that enlicitide prevents serious adverse events; the important safety reading is narrower. Serious events were not increased in the enlicitide arm during the 52-week controlled period.

Discontinuation due to adverse events was also not higher with enlicitide: 3.1% versus 4.1% with placebo. [3] This is one of the more clinically durable pieces of the safety profile. Patients can report many symptoms and still remain on therapy; discontinuation tells us whether the balance of symptoms, concern, and clinician judgment pushed treatment to a stop. In this trial, that did not happen more often with enlicitide.

Mortality was identical at 0.7% in both arms. [3] That figure should be read as a safety observation from a lipid-lowering trial, not as evidence about cardiovascular outcome benefit. The FDA has stated that it is not yet known whether Lipfendra reduces cardiovascular morbidity or mortality. [1]

The adverse reactions to name before prescribing

The safety profile is not symptom-free. The two adverse reactions that separated from placebo in the available evidence were dizziness and diarrhea, identified in the heterozygous familial hypercholesterolemia population. Dizziness was reported in 9% of enlicitide-treated patients versus 4% with placebo, and diarrhea in 7% versus 2%. [1]

Those percentages are not high enough to overturn the broader tolerability picture, but they are high enough to belong in the first conversation with a patient. Dizziness is a symptom that can be misattributed in either direction. A patient taking antihypertensives may assume it is blood pressure-related; a clinician may assume the same. The cleaner approach is to document timing, orthostatic symptoms, hydration status, blood pressure readings when available, and whether episodes began after enlicitide initiation or dosing routine changes.

Diarrhea needs the same practical handling. It may be mild and self-limited, but in a patient already taking metformin, magnesium, GLP-1 receptor agonists, bile acid sequestrants, or over-the-counter supplements, attribution can quickly become untidy. The trial signal gives clinicians permission to take the complaint seriously without assuming it requires immediate discontinuation. Severity, persistence, dehydration risk, weight change, and competing medication causes matter more than the label name alone.

• For dizziness: ask about timing after dosing, falls or near-falls, orthostatic symptoms, home blood pressure, and recent antihypertensive changes.
• For diarrhea: ask about onset, stool frequency, duration, fluid intake, metformin or GLP-1 use, magnesium-containing products, and whether symptoms affect adherence.
• For both: record whether symptoms improve with brief supportive management or recur after continued exposure.

That is the clinical middle ground the trial data point toward. Dizziness and diarrhea are not background noise to ignore, yet the pivotal discontinuation data do not suggest that adverse effects commonly forced patients off enlicitide during 52 weeks of controlled follow-up. [3]

What AddOn and adherence data add

CORALreef AddOn answers a different question. It was shorter, smaller, and active-comparator rather than placebo-controlled: 301 participants were followed for 8 weeks while enlicitide was compared with bempedoic acid, ezetimibe, or their combination. [4] It therefore should not displace CORALreef Lipids as the main safety denominator. Still, it is relevant because it places the oral PCSK9 inhibitor beside other oral LDL-C-lowering options.

In CORALreef AddOn, no serious adverse events occurred in the enlicitide arm, compared with 8% in the bempedoic acid arm. No deaths and no drug-induced liver injury were reported across any treatment arm. [4] The result is supportive, especially for early tolerability, but its 8-week duration leaves the longer safety burden with the 52-week placebo-controlled trial.

Adherence is also worth separating from safety rather than blending the two. Across the CORALreef program, 97% of participants took all or nearly all doses, and more than 95.9% followed dosing instructions correctly. [5] That is a strong signal that once-daily oral administration was workable inside a trial protocol. It does not prove that patients in routine practice will have the same adherence, but it reduces one concern: the tablet was not merely tolerated in theory while participants quietly failed to take it.

Signals that were not seen

Two absences matter in a cardiometabolic prescribing population. No drug-induced liver injury signal was detected in the available CORALreef evidence, including the AddOn comparison. [4][5] That finding is relevant because lipid-lowering regimens often accumulate in patients already being monitored for liver enzymes because of statins, metabolic dysfunction-associated steatotic liver disease, alcohol use, or other medications.

No new-onset diabetes signal was detected. [5] This should be stated carefully. The available evidence does not show a diabetes signal; it does not prove that every higher-risk subgroup has been characterized for very-long-term glycemic effects. For clinicians treating patients with insulin resistance, prediabetes, or established diabetes, the current reading is reassuring but still bounded by trial duration and eligibility criteria.

Where the safety evidence stops

The main controlled safety window is 52 weeks. [3] That is enough to identify many common and medium-term tolerability problems, but it is not the same as multi-year exposure in a broad population. LDL-C-lowering therapy is usually intended for chronic use, so rare events, cumulative tolerability issues, and adherence patterns after the trial structure falls away remain surveillance questions.

The trial population also matters. The available safety data come from clinical studies with eligibility criteria, including exclusions such as severe renal impairment, uncontrolled diabetes, and high triglycerides. [3][5] Real prescribing will include patients who are older, more medically complex, less adherent, and more likely to have overlapping symptoms at baseline. Comparable-to-placebo in CORALreef should not be translated into symptom-proof in every future patient.

There are also evidence gaps in specific populations. Pediatric data are not yet available; CORALreef Pediatric is ongoing. There are no data in homozygous familial hypercholesterolemia. [5] Those gaps are not unusual at initial approval, but they are important for clinicians who may otherwise generalize from an adult hypercholesterolemia program to every inherited lipid disorder.

The oral formulation introduces one additional uncertainty not shared with injectable PCSK9 inhibitors. Enlicitide uses sodium caprate as a permeation enhancer, and that component was not present in placebo. The AddOn publication noted this as a limitation, although no adverse events were attributed to it. [4] The prudent interpretation is not that sodium caprate has caused a demonstrated safety problem in this program; it is that longer and broader exposure will be needed to reduce uncertainty around gastrointestinal and absorptive effects.

Nor is there a head-to-head safety comparison with injectable PCSK9 inhibitors. The target is shared, but the route and formulation are different. For a patient who refuses injections, enlicitide may remove a major barrier. For a patient already stable on an injectable PCSK9 inhibitor, the safety comparison cannot be made from direct trial evidence.

The clinical reading after approval

For adults resembling the CORALreef populations, enlicitide’s trial safety profile is reassuring. The pivotal placebo-controlled trial did not show excess serious adverse events, adverse-event discontinuations, or mortality, and the overall adverse-event rate was close to placebo. [3] The symptoms clinicians should specifically anticipate are dizziness and diarrhea, particularly because those are the reactions that exceeded placebo rates in the HeFH data. [1]

The longer view is still open. CORALreef Outcomes is enrolling more than 14,500 participants, with results expected around 2029, and the cardiovascular outcomes benefit of Lipfendra has not yet been established. [1][6] Until those data and real-world experience mature, the most accurate judgment is bounded but favorable: enlicitide appears broadly placebo-comparable in controlled adult hypercholesterolemia trials, with dizziness and diarrhea as the main adverse reactions to monitor.

References

1. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol. FDA.
2. Merck’s Lipfendra (enlicitide) is the first and only once-daily oral PCSK9 inhibitor approved by the U.S. FDA to reduce LDL-C in adults with hypercholesterolemia. Merck.
3. CORALreef Lipids primary results. NEJM. 2026.
4. CORALreef AddOn results. JACC.
5. Efficacy and safety of enlicitide, an oral PCSK9 inhibitor. UT Southwestern physician update.
6. FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol. AJMC.